公开(公告)号：US20170190694A1

公开(公告)日：2017-07-06

申请号：US15466088

申请日：2017-03-22

申请人： Teijin Pharma Limited

发明人： Akinobu MARUYAMA ,  Hirofumi KAMADA ,  Mika FUJINUMA ,  Susumu TAKEUCHI ,  Hiroshi SAITOH ,  Yoshimasa TAKAHASHI

IPC分类号： C07D409/14 ,  C07D401/14 ,  C07D491/048 ,  C07D401/04 ,  C07D401/12

CPC分类号： C07D409/14 ,  A61K31/4439 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D491/048 ,  A61K2300/00

摘要： Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.

公开(公告)号：US20170217948A1

公开(公告)日：2017-08-03

申请号：US15329695

申请日：2015-07-29

申请人： Teijin Pharma Limited

发明人： Takashi SHIRAKURA ,  Yoshimasa TAKAHASHI ,  Asahi KAWANA ,  Chikashi KANAZAWA

IPC分类号： C07D417/10 ,  C07D417/14

CPC分类号： C07D417/10 ,  A61K31/427 ,  C07D417/14

摘要： Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.

公开(公告)号：US20180244665A1

公开(公告)日：2018-08-30

申请号：US15968227

申请日：2018-05-01

申请人： Teijin Pharma Limited

发明人： Takashi SHIRAKURA ,  Yoshimasa TAKAHASHI ,  Asahi KAWANA ,  Chikashi KANAZAWA

IPC分类号： C07D417/10 ,  C07D417/14

CPC分类号： C07D417/10 ,  A61K31/427 ,  C07D417/14

摘要： Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.

公开(公告)号：US20170152242A1

公开(公告)日：2017-06-01

申请号：US15310337

申请日：2015-05-12

申请人： TEIJIN PHARMA LIMITED

发明人： Akinobu MARUYAMA ,  Susumu TAKEUCHI ,  Yoshimasa TAKAHASHI

IPC分类号： C07D403/04 ,  C07D403/14 ,  C07D401/14 ,  C07D409/14

CPC分类号： C07D403/04 ,  A61K31/497 ,  C07D401/14 ,  C07D403/14 ,  C07D409/14

摘要： Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.

公开(公告)号：US20160039784A1

公开(公告)日：2016-02-11

申请号：US14774517

申请日：2014-03-28

申请人： TEIJIN PHARMA LIMITED

发明人： Asahi KAWANA ,  Chikashi KANAZAWA ,  Masayuki TERA ,  Yoshimasa TAKAHASHI ,  Mariko IMAZEKI ,  Hiroyuki TAKAHASHI ,  Akira TANOKURA

IPC分类号： C07D401/04 ,  C07D405/14 ,  C07D401/14 ,  C07D409/14

CPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

摘要： Provided are a compound expressed by formula (I) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [In the formula, A, X, Y, Z, R, and R1 have the meaning set forth in claim 1].

摘要翻译： 提供由式（I）表示的化合物或其药理学上允许的盐，以及含有该化合物作为活性成分的药物或药物组合物，其具有黄嘌呤氧化酶抑制作用，其对于治疗或预防 由黄嘌呤氧化酶，如痛风，高尿酸血症，肿瘤溶解综合征，尿路结石，高血压，血脂异常，糖尿病，心力衰竭和动脉硬化等心血管疾病，肾脏疾病如糖尿病近不透明度等引起的呼吸道疾病 如慢性阻塞性肺病等，自身免疫性疾病如炎症性肠病等。 [式中，A，X，Y，Z，R和R 1具有权利要求1所述的含义。

公开(公告)号：US20150376174A1

公开(公告)日：2015-12-31

申请号：US14442752

申请日：2014-01-30

申请人： TEIJIN PHARMA LIMITED

发明人： Asahi KAWANA ,  Chikashi KANAZAWA ,  Yoshimasa TAKAHASHI ,  Takashi SHIRAKURA

IPC分类号： C07D417/10

CPC分类号： C07D417/10

摘要： The present invention provides: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.

摘要翻译： 本发明提供：对式（I）表示的化合物或其药学上可接受的盐对黄嘌呤氧化酶具有优异的抑制活性，可用作与黄嘌呤氧化酶相关的疾病如痛风的治疗剂或预防剂 高尿酸血症，肿瘤溶解综合征，尿路结石，高血压，血脂异常，糖尿病，包括动脉硬化和心力衰竭的心血管疾病，肾病，包括糖尿病肾病，呼吸系统疾病，包括慢性阻塞性肺病，炎性肠病或自身免疫性疾病; 以及包含所述化合物或所述盐作为活性成分的药物或药物组合物。